首页 | 本学科首页   官方微博 | 高级检索  
检索        

前列腺癌、前列腺增生症患者血清骨保护素测定的临床价值
引用本文:赵雪志,李纲,王振杰,俞弘颀,浦金贤,严春寅,孙清,陈齐峰,印荣.前列腺癌、前列腺增生症患者血清骨保护素测定的临床价值[J].现代泌尿外科杂志,2011,16(5):443-445.
作者姓名:赵雪志  李纲  王振杰  俞弘颀  浦金贤  严春寅  孙清  陈齐峰  印荣
作者单位:1. 苏州市立医院北区泌尿外科,江苏苏州,215008
2. 苏州大学附属第一医院泌尿外科,江苏苏州,215007
3. 兴化市人民医院,江苏兴化,225000
摘    要:目的探讨前列腺癌(PCa)患者和前列腺增生(BPH)症患者血清中骨保护素(OPG)浓度的差异以及前列腺癌患者骨保护素浓度与血清前列腺特异性抗原(PSA)水平、前列腺体积是否具有相关性。方法采用双抗体夹心酶免法(ELISA)测定40例前列腺癌患者及40例前列腺增生患者血清OPG浓度,同时采集PCa患者的前列腺体积及PSA值。比较PCa患者及BPH患者血清OPG浓度的差异以及前列腺癌患者中OPG浓度与PSA、前列腺体积之间有无相关性。结果 PCa患者的血清OPG浓度平均值水平〔(14 900.19±5 168.65)pg/mL〕显著高于BPH组〔(10 457.87±4 786.29)pg/mL〕,差异有显著性意义(P〈0.01)。PCa患者血清OPG浓度与PSA值及前列腺体积之间均无明显相关性(r分别为=0.221、0.138,P均〉0.1)。结论血清OPG浓度对鉴别PCa和BPH有重要临床价值,PCa患者血清OPG浓度与血清PSA值及前列腺体积无明显相关性。

关 键 词:骨保护素  前列腺癌  前列腺增生症  前列腺特异抗原

The clinical value of serum concentration of osteoprotegerin in prostatic carcinoma and hyperplasia
ZHAO Xue-zhi,LI Gang,WANG Zhen-jie,YU Hong-qi,PU Jin-xian,YAN Chun-yan,SUN Qing,CHEN Qi-feng,YIN Rong.The clinical value of serum concentration of osteoprotegerin in prostatic carcinoma and hyperplasia[J].Journal of MOdern Urology,2011,16(5):443-445.
Authors:ZHAO Xue-zhi  LI Gang  WANG Zhen-jie  YU Hong-qi  PU Jin-xian  YAN Chun-yan  SUN Qing  CHEN Qi-feng  YIN Rong
Institution:ZHAO Xue-zhi1,LI Gang2,WANG Zhen-jie3,YU Hong-qi1,PU Jin-xian2,YAN Chun-yan2,SUN Qing1,CHEN Qi-feng1,YIN Rong1(1.Department of Urology,Suzhou Municipal Hospital,Suzhou 215008,2.Department of Urology,the First Affiliated Hospital of Suzhou University,Suzhou 215007,3.Department of Urology,Xinghua People's Hospital,Xinghua 225000,China)
Abstract:Objective To evaluate the significance of serum osteoprotegerin(OPG) in assessing prostate cancer(PCa) and benign prostatic hyperplasia(BPH),and to determine the correlation between concentration of OPG and serum PSA value and prostate volume.Methods The concentration of OPG was measured with ELISA in 40 patients with prostatic carcinoma and 40 patients with BPH.The relationship between OPG concentrations and PSA or prostate volume was calculated in patients with PCa.Results The OPG concentration was(14 900...
Keywords:osteoprotegerin  prostatic carcinoma  prostate hyperplasia  prostate-specific antigen  
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号